Markets › United States › NAS › MREO

Mereo BioPharma Group PLC

NAS:MREOHealthcarenasdaq_composite

$0.2801−2.54%LiveIn session · ≈ AED 1.03 · Market cap $45.3M · Next earnings Mon 9 Nov

Ratio	FY2020	FY2021	FY2022	FY2023	FY2024	FY2025	Current · undated	YoY
Gross margin	—	50.9%	—	74.3%	—	73.4%	—	—
Operating margin	—	−57.4%	—	−284.2%	—	−7,651.4%	−7,651.4%	+0.0 pts
Net margin	—	34.9%	—	−294.7%	—	−8,375.6%	−8,375.6%	+0.0 pts
EBITDA margin	—	51.8%	—	−260.6%	—	−8,094.8%	—	—
Return on equity	1,024.9%	14.4%	−81.9%	−58.3%	−70.9%	−102.4%	−102.4%	+0.0 pts
Return on assets	−243.8%	10.0%	−54.4%	−44.3%	−56.6%	−91.2%	−91.2%	+0.0 pts
Return on capital employed	−64.8%	−18.3%	−101.2%	−49.8%	−75.7%	−91.9%	—	—
Debt / equity	−1.2×	0.2×	0.3×	0.1×	0.1×	0.0×	0.0×	+0.0%
Debt / assets	28.5%	13.3%	19.9%	9.0%	8.4%	0.4%	—	—
Interest coverage	−7.5×	−5.4×	−16.0×	−9.9×	−34.6×	−150.0×	—	—
Current ratio	3.5×	7.9×	3.1×	6.7×	5.4×	10.5×	10.5×	+0.0%
Quick ratio	3.5×	7.9×	3.1×	6.7×	5.4×	10.5×	—	—
Cash ratio	2.7×	7.5×	2.8×	6.1×	5.0×	9.5×	9.5×	+0.0%
Asset turnover	0.0×	0.3×	0.0×	0.2×	0.0×	0.0×	—	—
Receivables turnover	—	—	—	2.7×	0.0×	0.3×	—	—
Dividend payout	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	—	—